Plasma proteomic profiling identifies apolipoprotein A4 as a downregulated biomarker of adrenocortical carcinoma: a multi-platform discovery and validation study
European Journal of Endocrinology · 30.04.2026 · 194 (5) · 641-652
DOI: 10.1093/ejendo/lvag079 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift European Journal of Endocrinology, online erschienen am 07.05.2026. Verfasst von Seung Shin Park und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Apolipoproteins A, Adrenocortical Carcinoma, Adrenal Cortex Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Korea Health Technology R&D Project, Korea Health Industry Development Institute, Ministry of Health.
Abstract (Originalsprache)
Objectives
Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy associated with heterogeneous prognosis. Preoperative differentiation from adrenocortical adenoma (ACA) remains challenging, and no serum tumor marker has been established. We aimed to identify circulating protein biomarkers that distinguish ACC from ACA using a stepwise, multiplatform proteomics strategy.
Methods
We assembled discovery (ACC = 10, ACA = 67) and verification (ACC = 7, ACA = 11) cohorts from a tertiary center and profiled fasting plasma using liquid chromatography-mass spectrometry (LC-MS/MS) with data-independent acquisition. Differentially expressed proteins (DEPs) were defined by t-tests with P < .05 and |fold-change| >1.2; DEPs common to both cohorts were prioritized. Targeted validation by parallel reaction monitoring (PRM) used an expanded, two-center cohort including additional cases from Asan Medical Center (ACC = 31; ACA = 78). Orthogonal validation employed the Olink Explore 384 Inflammation II panel in an independent set (ACC = 15; ACA = 24).
Results
The discovery cohort yielded 67 DEPs (22 upregulated and 45 downregulated in ACC), and the verification cohort identified 17 DEPs. Three proteins, CD44, proteoglycan 4, and apolipoprotein A4 (APOA4), were common to both analyses and were underexpressed in ACC compared with ACA. In PRM, CD44 and APOA4 showed directionally concordant, significant decreases in ACC, prioritizing these markers for further evaluation. In the Olink analysis, 40 proteins differed between ACC and ACA after false discovery rate correction; APOA4 remained significantly lower in ACC.
Conclusion
Across discovery, targeted, and orthogonal platforms, APOA4 consistently exhibited lower circulating levels in ACC, supporting its potential as a serum biomarker for the preoperative differentiation of ACC from ACA. External, multiethnic validation and clinically deployable assays, alone or within multimarker panels, are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Transdisciplinary Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
- Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, Asan Medical Center, Seoul, 05505, Republic of Korea.
ORCID-Profile: Seung Hun Lee, Kyu Eun Lee, Dohyun Han, Jung Hee Kim
Förderung
- Korea Health Technology R&D Project
- Korea Health Industry Development Institute
- Ministry of Health
- Welfare of the Republic of Korea
- Korean Endocrine Society
- National Research Foundation of Korea
Zitieren
APA
Park, S. S., Seo, H., Moon, S. J., Jang, H. N., Lee, S. H., Kim, S. J., Lee, K. E., Han, D., & Kim, J. H. (2026). Plasma proteomic profiling identifies apolipoprotein A4 as a downregulated biomarker of adrenocortical carcinoma: a multi-platform discovery and validation study. European Journal of Endocrinology, 194(5), 641-652. https://doi.org/10.1093/ejendo/lvag079
Vancouver
Park SS, Seo H, Moon SJ, Jang HN, Lee SH, Kim SJ, et al. Plasma proteomic profiling identifies apolipoprotein A4 as a downregulated biomarker of adrenocortical carcinoma: a multi-platform discovery and validation study. European Journal of Endocrinology. 2026;194(5):641-652. doi:10.1093/ejendo/lvag079
BibTeX
@article{Park2026,
author = {Park, Seung Shin and Seo, Hoseok and Moon, Sun Joon and Jang, Han Na and Lee, Seung Hun and Kim, Su-Jin and Lee, Kyu Eun and Han, Dohyun and Kim, Jung Hee},
title = {Plasma proteomic profiling identifies apolipoprotein A4 as a downregulated biomarker of adrenocortical carcinoma: a multi-platform discovery and validation study},
journal = {European Journal of Endocrinology},
year = {2026},
volume = {194},
number = {5},
pages = {641--652},
doi = {10.1093/ejendo/lvag079}
}
EUVIMED